Tegafur: Clinical Trials

28 trials of Tegafur, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 unknown, 9 completed, 4 recruiting, 3 terminated. 28 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 328Unknown 10, Completed 9, Recruiting 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1
Phase 25Unknown 2, Completed 1, Recruiting 1, Terminated 1

Follow Tegafur: new trials by email Literature Review of Tegafur trials Research Report on Tegafur

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7202026-07-312026-08-14
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
GFH375, Chemotherapy - Metastatic Pancreatic Cancer
Phase 3RecruitingGenfleet Therapeutics (Shanghai) Inc.3202025-12-042026-08-14
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer
Phase 3Active not recruitingAstraZeneca7602023-12-042026-10-16
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
Envolimab, Fruquintinib, Oxaliplatin - Gastric Cancer
Phase 3Not yet recruitingFujian Medical University1002023-09-012023-08-25
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy
Phase 2 / Phase 3UnknownTaizhou Hospital602022-07-012023-04-18
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Tislelizumab in Combination with Oxaliplatin and Tegafur - Liver Metastases
Phase 2 / Phase 3UnknownZhejiang University402022-04-102023-02-01
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Lerotinib, Irinotecan/Tegafur - Esophageal Cancer
Phase 3RecruitingSunshine Lake Pharma Co., Ltd.4162021-01-212026-09-28
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
nab paclitaxel, Tegafur, Oxaliplatin - Stomach Cancer
Phase 3UnknownZhejiang Cancer Hospital6162020-03-012020-03-23
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
S-1 for 9 months, S-1 for 1 year - Gastric Cancer
Phase 3RecruitingFudan University10062019-01-012019-05-31
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
Oxaliplatin, Paclitaxel, S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules) - Gastric Cancer, Stomach Neoplasms
Phase 3UnknownFudan University2152018-03-162018-03-23
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
MEP - Nasopharyngeal Carcinoma
Phase 3TerminatedNational Health Research Institutes, Taiwan102014-12-142025-08-19
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Tegafur, Gimeracil and Oteracil Potassium Capsules;Oxaliplatin, Oxaliplatin; Capecitabine - Gastric Cancer
Phase 2 / Phase 3CompletedHebei Medical University7492012-02-012020-02-13
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) - Gastric Cancer
Phase 3CompletedSanofi5302011-12-302023-12-13
Trial of S-1 Plus Cisplatin in Gastric Cancer
s-1 plus cisplatin, 5-Fu plus cisplatin - Gastric Cancer
Phase 3UnknownSun Yat-sen University2702008-09-012011-07-25
Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
folinate calcium, tegafur-uracil, tegafur-gimeracil-oteracil potassium - Colorectal Cancer
Phase 3CompletedTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan15352008-04-012016-08-03
Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer
UFT, Calcium Folinate, PSK, UFT, Calcium Folinate - Colorectal Cancer
Phase 3UnknownIwate Medical University3002007-07-012008-07-31
Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK), Tegafur/gimeracil/oteracil potassium (S-1) - Gastric Cancer
Phase 2 / Phase 3TerminatedEastern Network of Cancer Immunological Therapy, Japan132006-10-012009-01-23
Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery
UFT adjuvant chemotherapy - Colorectal Cancer
Phase 3CompletedTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan20252006-10-012016-09-28
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy - Head and Neck Cancer
Phase 3UnknownYokohama City University5002006-04-012013-05-15
A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
Tegafur-uracil (UFT), Calcium folinate (LV), Krestin (PSK) - Colorectal Cancer
Phase 3UnknownMulticenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group3802006-03-012012-10-26

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Stomach Neoplasms (10)  ·  Colorectal Neoplasms (7)  ·  Colonic Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Esophageal Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Bile Duct Neoplasms (1)  ·  Biliary Tract Neoplasms (1)  ·  Cholangiocarcinoma (1)  ·  Epstein-Barr Virus Infections (1)  ·  Gallbladder Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Klatskin Tumor (1)  ·  Lung Neoplasms (1)  ·  Nasopharyngeal Carcinoma (1)

Sponsors

Taiho Pharmaceutical Co., Ltd. (4)  ·  Fudan University (2)  ·  Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (2)  ·  AstraZeneca (1)  ·  Eastern Network of Cancer Immunological Therapy, Japan (1)  ·  Fujian Medical University (1)  ·  Genfleet Therapeutics (Shanghai) Inc. (1)  ·  Hebei Medical University (1)  ·  Hokkaido Gastrointestinal Cancer Study Group (1)  ·  Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)  ·  Institut Cancerologie de l'Ouest (1)  ·  Iwate Medical University (1)  ·  Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (1)  ·  NSABP Foundation Inc (1)  ·  National Health Research Institutes, Taiwan (1)

Countries

Japan (13)  ·  China (11)  ·  France (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Denmark (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  India (1)  ·  Italy (1)  ·  Norway (1)

Top investigators

Kenichi Sugihara, MD, PhD (2)  ·  Chia-Jui Yen Yen, MD. PhD (1)  ·  Ching-Yun Hsieh, MD (1)  ·  Christian Chevelle, MD (1)  ·  Dazhi Xu, PHD, MD (1)  ·  Go Wakabayashi, MD, PhD (1)  ·  Hideaki Tahara, MD (1)  ·  Hirohito Tada, MD (1)  ·  Hiroki Koyama, MD (1)  ·  Hsiao-Hui Tsou, PhD (1)  ·  JianMing Xu, Doctor (1)  ·  Jin-Ching Lin, MD, PHD (1)  ·  Jin-Ching Lin, MD, PhD (1)

Results publications

PMID 11098486, PMID 16648506, PMID 16675478, PMID 16945170, PMID 17264338, PMID 17948223, PMID 19204202, PMID 19638976, PMID 22769569, PMID 24942277, PMID 25671770, PMID 26439700, PMID 29677641, PMID 30425843, PMID 31180819, PMID 32583567, PMID 33435909, PMID 34133211, PMID 37501640, PMID 38996201

NIH funding

2023 (1), U10CA012027 (1)